Duncan Crow
Wholistic Consultant
http://members.shaw.ca/SomaLife-gHP/HGH_osteo_medline.html
HGH Deficiency in Osteoporosis
In each of these cases you can go to the Medline site http://www.ncbi.nlm.nih.gov/entrez/query.fcgi and enter the PMID number to bring up the abstract.
__________________________________________
Celiker R, Arslan S.
Comparison of serum insulin-like growth factor-1 and growth hormone levels in osteoporotic and non-osteoporotic postmenopausal women.
Rheumatol Int 2000;19(6):205-8
PMID: 11063288 [PubMed - indexed for MEDLINE]
Hacettepe University School of Medicine, Department of Physical Medicine and Rehabilitation, Ankara, Turkey. celiker@tr-net.net.tr
BACKGROUND: The purpose of this study was to compare the insulin-like growth factor-1 (IGF-1) levels and the growth hormone (GH) levels in osteoporotic and non-osteoporotic postmenopausal women.
CONCLUSIONS: When compared with normal postmenopausal women, IGF-1 levels were found to be lower in women with osteoporosis. IGF-1 seems to play an important role in the development of low bone mass and the present results suggest that IGF-1 is a useful predictor of the presence of osteoporosis.
__________________________________________
Monson JP, Drake WM, Carroll PV, Weaver JU, Rodriguez-Arnao J, Savage MO.
Influence of growth hormone on accretion of bone mass.
Horm Res 2002;58 Suppl 1:52-6
PMID: 12373015 [PubMed - in process]
Department of Endocrinology, St Bartholomew's Hospital, London, UK.
Growth hormone (GH) exerts important influences on bone metabolism during lifespan. During childhood, GH is a major determinant of acquisition of bone mass and in adult life, GH partly determines the rate of bone remodelling and therefore influences maintenance of bone mineral density. GH replacement in adult-onset GH deficiency results in an early increment in indices of bone remodelling which persists for up to 5 years.
__________________________________________
Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K.
Effect of recombinant human growth hormone in elderly osteoporotic women.
Clin Endocrinol (Oxf) 1999 Dec;51(6):715-24
PMID: 10619976 [PubMed - indexed for MEDLINE]
Third Division, Department of Medicine, Kobe University School of Medicine, Kobe, Japan.
OBJECTIVE: Bone mineral density and growth hormone (GH) secretion rate both decline during normal human aging. We evaluated the effects of recombinant human GH on markers of body composition and bone turnover in an open study in 8 elderly osteoporotic women aged 68-75 years (mean age 71 years).
CONCLUSION: These results indicate that GH attenuates the decrease in muscle strength and bone mass as well as the gain of abdominal fat with aging in elderly women. The present data provide useful information about the application of GH treatment in elderly women.
__________________________________________
Sugimoto T, Kaji H, Nakaoka D, Yamauchi M, Yano S, Sugishita T, Baylink DJ, Mohan S, Chihara K.
Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis.
Eur J Endocrinol 2002 Sep;147(3):339-48
PMID: 12213671 [PubMed - in process]
Division of Endocrinology/Metabolism, Neurology and Hematology/Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
BACKGROUND: There has been increasing evidence that the growth hormone (GH)-IGF-I axis plays an important part in the maintenance of bone mass. However, controversy still exists as to the effect of GH treatment on bone mineral density in elderly patients with osteoporosis.
CONCLUSIONS: Low-dose GH treatment attenuated the decrease in muscle strength and bone mass in elderly women without side effects, although changes in nutrition and exercise might affect BMD. The present findings provide useful information regarding the use of low-dose GH treatment in elderly women with osteoporosis.
__________________________________________
Attie KM.
The importance of growth hormone replacement therapy for bone mass in young adults with growth hormone deficiency.
J Pediatr Endocrinol Metab 2000 Sep;13 Suppl 2:1011-21
PMID: 11086656 [PubMed - indexed for MEDLINE]
Department of Medical Affairs, Genentech, Inc., South San Francisco, CA 94080, USA. kma@gene.com
GH deficiency (GHD) is associated with reduced bone turnover and decreased bone mineral density (BMD), especially in patients with childhood-onset GHD. GH replacement therapy stimulates bone remodeling and causes an initial decrease in BMD due to bone resorption and expansion of the remodeling space. This is followed by increased bone formation and a significant increase in BMD that continues with prolonged GH therapy.
__________________________________________
Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R.
The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial.
J Bone Miner Res 2002 Jun;17(6):1081-94
PMID: 12054164 [PubMed - in process]
Department of Endocrinology, University Hospital Gasthuisberg, Leuven, Belgium.
BACKGROUND: Adult hypopituitary patients with growth hormone deficiency (GHD) show a significant decrease in bone mass and an increased fracture rate. Replacement therapy with GH increases bone turnover.
CONCLUSION: A significant increase in spine BMC (bone mineral content) and BMD (bone mineral density) and total hip BMD and a decrease in BMD at the ultradistal radius over time was observed in male GH-treated patients compared with the evolution in controls. Despite the increase in the total remodeling space induced by GH treatment, prolonged GH therapy in adult-onset GHD has a positive effect on bone balance, maintaining bone mass in women, and even increasing it in men over a 2 year-period.
HGH therapy Home page
webbed by: